| Literature DB >> 21160526 |
Chad V Pecot1, George A Calin, Robert L Coleman, Gabriel Lopez-Berestein, Anil K Sood.
Abstract
Inherent difficulties with blocking many desirable targets using conventional approaches have prompted many to consider using RNA interference (RNAi) as a therapeutic approach. Although exploitation of RNAi has immense potential as a cancer therapeutic, many physiological obstacles stand in the way of successful and efficient delivery. This Review explores current challenges to the development of synthetic RNAi-based therapies and considers new approaches to circumvent biological barriers, to avoid intolerable side effects and to achieve controlled and sustained release.Entities:
Mesh:
Year: 2010 PMID: 21160526 PMCID: PMC3199132 DOI: 10.1038/nrc2966
Source DB: PubMed Journal: Nat Rev Cancer ISSN: 1474-175X Impact factor: 60.716